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Abstract
Elevated rates of substance use (alcohol, tobacco, cannabis) have been reported in people at
clinical high risk (CHR) of developing psychosis and there is some evidence that substance use
may be higher in those who convert to a psychosis compared to non-converters. However little is
known about the predictive value of substance use on risk of conversion to psychosis in those at
CHR of psychosis. In the current study, 170 people at CHR of psychosis were assessed at baseline
on severity of alcohol, tobacco and cannabis using the Alcohol and Drug Use Scale. Participants
were recruited across three sites over a four year period as part of the Enhancing the Prospective
Prediction of Psychosis (PREDICT) study. Predictors of conversion to psychosis were examined
using Cox proportional hazards models. Results revealed that low use of alcohol, but neither
cannabis use nor tobacco use at baseline contributed to the prediction of psychosis in the CHR
sample. Prediction algorithms incorporating combinations of additional baseline variables known
to be associated with psychotic conversion may result in increased predictive power compared
with substance use alone.
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In a recent review, Addington and colleagues (Addington et al., in press) identified ten
studies that examined substance use in people who are at clinical high risk (CHR) of
developing psychosis. Across these studies, the most commonly used substances were
cannabis, alcohol and tobacco, with cannabis and tobacco use being higher than in healthy
controls (Auther et al., 2012), and with rates similar to those experiencing a first-episode of
psychosis (Barnett et al., 2007; Cooper et al., 2012; Sevy et al., 2001). Fewer studies have
examined the relationship between substance use and conversion to psychosis in CHR.
Cannon et al (Cannon et al., 2008) reported that a history of any substance abuse was one of
five predictors of conversion to psychosis in a multivariate model. Kristensen and
Cadenhead (Kristensen and Cadenhead, 2007 found that CHR individuals were more likely
to develop psychosis within one year if they had used tobacco or met criteria for cannabis
abuse/dependence. Several of the remaining studies examining substance use in those at
CHR have reported no significant relationships between severity of use and later conversion
to psychosis (Auther et al., 2012; Phillips et al., 2002; Ruhrmann et al., 2010; Thompson et
al., 2011). However, some studies evaluated cannabis only (Korver et al., 2010), or recorded
the use of any substance globally rather than multiple individual ones (Cannon et al., 2008;
Thompson et al., 2011). In addition, it may be important to consider the role of positive
symptoms as there is some evidence that cannabis use may be related to positive symptom
severity (Corcoran et al., 2008; Korver et al., 2010). Furthermore, the negative studies may
be underpowered to demonstrate a positive relation between substance use and conversion,
or employed statistical tests insensitive to the predictive value of substance use for psychosis
onset. As such, it is unclear whether there is an effect of substance use on conversion to
psychosis in CHR individuals.
Therefore, the aim of the current prospective study was to examine in a large, well
characterized sample of individuals at CHR of psychosis 1) severity of substance use at
baseline in people who converted to a psychosis compared to non-converters over a four
year period, and 2) the relationship between substance use at baseline and rate of conversion
to psychosis.
2. Materials and Methods
2.1 Sample
One-hundred and seventy (96 males, 74 females) individuals at CHR of psychosis
participated as part of a multi-site NIMH funded study “Enhancing the Prospective
Prediction of Psychosis” (PREDICT). This was a 4-year longitudinal observational study to
determine predictors of conversion to psychosis in individuals at CHR of developing
psychosis who were not using anti-psychotic medication. The study was conducted at the
Universities of Toronto, North Carolina, and Yale. All CHR individuals met the Criteria of
Prodromal States (COPS) based on the Structured Interview for Prodromal Syndromes
(SIPS) (McGlashan et al., 2010). One hundred sixty-seven CHR participants met attenuated
positive symptom syndrome (APSS) criteria, which includes the emergence or worsening of
a non-psychotic level disturbance in thought content, thought process or perceptual
abnormality over the past year, six participants met criteria for genetic risk and deterioration
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(GRD), which required either a first degree relative with a psychotic disorder or the subject
having schizotypal personality disorder plus at least a 30% drop in functioning on the
General Assessment of Functioning (GAF) scale in the past 12 months, and three
participants met both APSS and GRD.
Participants were excluded if they met criteria for any current or lifetime axis I psychotic
disorder, prior history of treatment with an antipsychotic, IQ<70, or past or current history
of a clinically significant central nervous system disorder that may confound or contribute to
clinical high risk symptoms, or using antipsychotics at baseline. Antipsychotics were not
used at any later points in this study.
2.2 Measures
Criteria for a prodromal syndrome and for conversion to psychosis were determined using
the SIPS (McGlashan et al., 2010). Conversion meant that at least one of the five attenuated
positive symptoms reached a psychotic level of intensity (rated 6) for a frequency of ≥1
hour/day for 4 days/week during the past month or that symptoms seriously impacted
functioning (e.g. severely disorganized or dangerous to self or others). Symptoms were
assessed with the Scale of Prodromal Symptoms (SOPS), which consists of 19 items in 4
symptom domains: positive, negative, general, and disorganized.
Participants were rated on substance use with a well-established rating scale, the Alcohol
and Drug Use Scale (AUS/DUS) (Drake et al., 1996). The AUS/DUS was used to record
severity of substance use within the past month. It is a 5-point scale with anchors that are
equivalent to 1=abstinent, 2=use without impairment, 3=abuse, 4=dependence and 5=severe
dependence. Ratings of 3 and 4 reflect behaviors equivalent to DSM-IV diagnoses of abuse
and dependence. Severity ratings were recorded for alcohol, tobacco, cannabis, cocaine,
opiates, PCP, amphetamine, MDMA, GHB, huffing, hallucinogens and other substances at
baseline.
2.3 Statistical Analysis
Differences in baseline characteristics of converters vs non-converters were evaluated by
either t-tests (continuous data), or χ2 or Fisher’s Exact tests (categorical data). Pearson’s rho
was used to correlate substance use with age and symptom severity. Substance use variables
were non-normally distributed and non-transformable; therefore, Mann Whitney U tests
were used to compare substance use severity at baseline between groups. Cox proportional
hazard regression models were used to estimate the association of substance use with
conversion to psychosis. The assumption of proportionality was violated for ratings of
tobacco use; therefore, ratings of 2–4 were combined as any use. The analysis of time to
conversion was calculated in days since entry into the study. Follow-up for non-converters
was calculated as the last date when SOPS ratings were acquired within 4 years. The effects
of risk factors are described by their Cox regression hazard ratio (HR) and 95% confidence
intervals. We first considered a model which included all the predictors that had a p-value
<0.25 in the univariate analyses, with an aim to drop the least significant variable, then
continue by successively refitting the model and applying the same backward elimination
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rule until all remaining variables were statistically significant. Statistical analyses were
conducted using SPSS 20.0 and SAS 3.0.
2.4 Procedures
All three sites involved in this longitudinal study of predictors of conversion to psychosis
recruited CHR individuals. Raters were experienced research clinicians who demonstrated
adequate reliability at routine reliability checks. Gold standard post-training agreement on
the critical threshold for determining initial eligibility and subsequent conversion status
based on the SIPS was excellent (kappa=.90). The PI or clinical psychiatrist or psychologist
at each site conducted a comprehensive clinical assessment to determine if entry criteria
were met. JA chaired weekly conference calls to review criteria for all individuals admitted
to the study. The study protocols and informed consents were reviewed and approved by the




The mean age of the sample was 19.7 years (SD=4.5). Demographic characteristics are
shown in Table 1. Converters and non-converters did not significantly differ on age, t=0.19,
p=0.90, gender, χ2=1.08, p=0.30, race, p=0.32, marital status, p=0.47, or education, p=0.41.
The use of substances other than alcohol, tobacco or cannabis was either minimal or absent,
therefore the use of these substances were not considered further in relation to demographic
variables, positive symptoms, or rate of conversion to psychosis. Age was significantly
associated with use of tobacco, r=0.24, p<0.01, and alcohol, r=0.42, p<0.01, but not
cannabis r=0.02, p=0.76. Males and females did not differ on tobacco, p=0.79, alcohol,
p=0.68 or cannabis use, p=0.79. Total SOPS positive symptom scores did not significantly
correlate with tobacco, r=0.04, p=0.63, alcohol, r=−0.10, p=0.22, or cannabis use, r=0.04,
p=0.59.
3.2 Substance use and risk of conversion to psychosis
Table 2 displays the number of participants receiving each of the ratings for the different
substance.
When examining AUS/DUS severity ratings, converters and non-converters significantly
differed in baseline alcohol use, U=1472.5, p<0.01, reflecting slightly lower use severity in
converters. Groups did not differ in tobacco, U=1752.5, P=0.13, or cannabis use, U=1790.0,
P=0.19.
The predictors of conversion to psychosis examined via Cox regression were: Baseline
alcohol, tobacco and cannabis use, and age. In the final model, reduced use of alcohol was
the only significant predictor of risk of conversion to psychosis, p<0.05. Compared to those
who used alcohol, those who did not use alcohol had 2.1% higher rate of conversion to
psychosis per unit time, HR=2.1, CI=1.02–4.28, p<0.05. There was no association between
tobacco or cannabis use at baseline and risk of conversion to psychosis.
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This multi-site study assessed prospectively the relationship between substance use at entry
into a CHR for psychosis research program and rate of conversion to psychosis. Total SOPS
positive symptoms did not significantly associate with use of alcohol, tobacco or cannabis.
Slightly but significantly lower alcohol use was observed in those who converted to
psychosis compared to non-converters. Low levels of alcohol use were associated with an
increased rate of conversion to psychosis. Neither tobacco nor cannabis use severity
predicted later conversion to psychosis; suggesting use of these substances did not
contribute to the rate of conversion to a psychotic disorder in this sample.
These results should be interpreted with caution. Tobacco, cannabis and alcohol use did not
increase the rate of conversion to psychosis, although it is possible that high endorsement of
abstinence and unimpaired substance use, and commensurately minimal prevalence of abuse
in the sample may limit sensitivity to detect an effect. The negative result between increased
substance use and rate of conversion to psychosis accords with conclusions of a recent
review of the literature (Addington et al., in press) on substance use in CHR, and suggests
that substance use may not contribute uniquely to the prediction of psychosis in people at
CHR of psychosis. Alcohol use with no impairment was limited in this sample of converters
and may be a proxy measure of being more sociable. It is noteworthy that the current sample
was larger and therefore greater powered than Kristensen and Cadenhead’s (Kristensen and
Cadenhead, 2007) sample of 48 CHR subjects, who demonstrated a relation between
cannabis abuse and later conversion to psychosis at 1 year, which could suggest a sensitivity
of the substance use effect to sample size.
It is important to note that the current prospective study lacks information on substance use
diagnoses in people at CHR of psychosis. In addition, substance use was not measured
longitudinally, and therefore the results cannot address potential changes in substance use
over time in this population. Interestingly, Cannon and colleagues (Cannon et al., 2008)
observed evidence for a relation between increased rate of conversion to psychosis and any
substance use when entered in a prediction algorithm along with four additional predictors
including psychopathology and social functioning. In this regard, it may be that the
importance of substance use could be through its interactive effects with other substances,
symptom severity or current level of functioning. The role of substance use for risk of
conversion may be better tapped by multivariate prediction algorithms incorporating
multiple variables implicated in psychosis onset, such as early trauma (Bechdolf et al.,
2010), genetic risk (Cannon et al., 2008) or social functional impairment (Gee and Cannon,
2011), and may be informative in future research.
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Table 1
Demographic characteristics of the sample
Non-converters (n=141) Converters (n=29)
Mean (SD) Range Mean (SD) Range
Age 19.8 (4.5) 12.0–31.0 19.7 (4.6) 12.3–31.2
N % N %
Gender (M:F) 82:59 59:41 14:15 48:52
Race
 Caucasian 113 79.6 19 65.5
 Black/African American 13 9.2 5 17.2
 Asian 9 6.3 3 10.3
 Native Hawaiian/Pacific Islander 1 0.7 0 0
 Other 5 3.5 2 6.9
Marital status
 Common law/Legal married 6 4.2 2 6.9
 Separated 2 1.4 0 0
 Never Married 134 94.4 27 93.1
Education
 Did not complete high school 61 43.0 13 44.8
 GED/High school diploma 14 0.7 1 3.4
 Some college, did not graduate 52 9.9 3 10.3
 Community college/technical degree 5 36.6 7 24.1
 College graduate 4 3.5 2 6.9
 College graduate and some Master’s level courses 3 2.8 2 6.9
 Master’s degree completed 2 2.1 1 3.4
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Table 2
Rates of drug use as reported in the AUS/DUS interview at baseline1.




N % N %
Alcohol
 Abstinent 56 39.7 20 68.9
 Use without impairment 81 57.5 8 27.6
 Abuse 3 2.1 0 0.0
 Dependence 1 0.7 1 3.4
Tobacco
 Abstinent 94 67.1 24 82.8
 Use without impairment 43 30.5 3 10.4
 Abuse 2 1.4 1 3.4
 Dependence 2 1.4 1 3.4
Cannabis
 Abstinent 95 67.4 23 79.3
 Use without impairment 33 23.4 5 17.3
 Abuse 11 7.8 0 0.0
 Dependence 2 1.4 1 3.4
Cocaine
 Abstinent 131 92.3 28 96.6
 Use without impairment 9 6.3 1 3.4
 Abuse 0 0.0 0 0.0
 Dependence 1 0.7 0 0.0
Opiates
 Abstinent 139 97.9 29 100.0
 Use without impairment 0 0.0 0 0.0
 Abuse 1 0.7 0 0.0
 Dependence 1 0.7 0 0.0
PCP
 Abstinent 141 100.0 29 100.0
Amphetamines
 Abstinent 138 97.9 29 100.0
 Use without impairment 3 2.1 0 0.0
MDMA
 Abstinent 135 95.7 28 96.6
 Use without impairment 6 4.3 1 3.4
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N % N %
GHB2
 Abstinent 139 98.6 29 100.0
 Use without impairment 1 0.7 0 0.0
Huffing
 Abstinent 140 99.3 29 100.0
 Use without impairment 1 0.7 0 0.0
Hallucinogens
 Abstinent 128 90.8 28 96.6
 Use without impairment 11 7.8 1 3.4
 Abuse 2 1.4 0 0.0
Other Substances
 Abstinent 135 95.7 29 100.0
 Use without impairment 6 4.3 0 0.0
1
Only ratings that were endorsed have been included in this table.
2
Data was missing for one participant in the non-converter group.
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